Company news
NRX Pharmaceuticals, Inc. news in 2023
NRX Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
December 26, 2023
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
December 18, 2023
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
December 17, 2023
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
December 12, 2023
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 12, 2023
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023
November 6, 2023
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
November 5, 2023
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression
October 30, 2023
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
October 25, 2023
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference
October 11, 2023
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain
October 1, 2023
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression
September 14, 2023
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support
September 13, 2023
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
September 5, 2023
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
August 29, 2023
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
August 28, 2023
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
August 6, 2023
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering
June 5, 2023
NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call
May 9, 2023
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
April 26, 2023
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
March 26, 2023
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
March 16, 2023
NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering
March 8, 2023
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio
February 21, 2023
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
February 12, 2023
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
February 1, 2023
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
January 18, 2023
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
January 4, 2023
NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted
January 2, 2023
Calls in 2023
- NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2023 Earnings Call
Nov 14, 2023
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2023 Earnings Call
Aug 14, 2023
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2023 Earnings Call
May 16, 2023
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2022 Earnings Call
Mar 30, 2023
Transcript
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 34 slides · June 2023